Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Myriad Genetics Inc. (MYGN - Analyst Report) disclosed a financial assistance program for underinsured patients. Following the move, it seems like this molecular diagnostic company has left no stone unturned to improve adoption rates for its market-leading diagnostic tests.

Per the program, effective Jul 22, Myriad will offer financial assistance to ensure lower out-of-pocket costs for qualified uninsured patients. Accordingly, the patients will pay no more than $375 for Myriad’s expensive diagnostic test line.

The expanded financial support from Myriad applies to the company’s entire portfolio of diagnostic tests. Patient eligibility depends upon private insurance, ability to meet insurance’s coverage criteria for testing and low income requirements (households living within 200% of the Federal poverty level).

The latest program will extend the company’s financial assistance program that currently offers free testing for low income uninsured patients (household income below 200% of the Federal poverty level) and interest-free tailored payment plans for all patients to accommodate specific financial situations. To date, over 35,000 patients have gained access to Myriad’s gamut of tests.

Based on Commonwealth Fund's 2012 Biennial Health Insurance Survey, about 30 million individuals in the U.S. remain uninsured. Furthermore, 80 million Americans skipped required health care (doctor’s visit and prescriptions) in 2012 due to cost constraints.

Considering the significant population of underinsured individuals in the U.S., Myriad’s financial support to patients is likely to improve adoption rates for its premium tests. We believe that the development should augur well for the long-term growth of the company. Nonetheless, the impact of the patent litigation and market conversion to its myRisk hereditary cancer test are areas of concern. Thus, we remain on the sidelines for Myriad.

The stock carries a Zacks Rank #3 (Hold). Other players such as Cepheid (CPHD - Analyst Report), Luminex Corporation (LMNX - Analyst Report) and MAKO Surgical Corp. appear impressive. These stocks carry a Zacks Rank #2 (Buy). 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%